ORAL FORMULATIONS FOR PROMOTING CELLULAR PURIFICATION
An oral formulation includes a plurality of agents that promote cellular detoxification. Agents can be included that modulate expression of Nrf2-associated genes upon ingestion of the oral formulation by a subject, wherein the Nrf2-associated genes include at least one gene encoding intrinsic antioxidants, and at least one gene encoding cellular detoxifiers. In addition, at least one of the plurality of agents attenuates inflammation.
1 - 64 . (canceled)
65 . A method for modulating expression of Nrf2-associated genes in a subject, comprising:
administering to the subject an oral formulation including at least three agents that modulate expression of Nrf2-associated genes at a dose that modulates the expression of the Nrf2-associated genes;
wherein the at least three agents that modulate the expression of the Nrf2-associated genes are members selected from the group consisting of broccoli seed extract, alpha lipoic acid, red orange extract, grape seed extract, whole grape extract, ginseng , olive leaf extract, olive fruit extract, coenzyme Q 10 , pomegranate extract, curcumin, EGCG, lutein, lycopene, zeaxanthin, resveratrol, Schizandra berry extract, tart cherry extract, rosemary extract, and Cordyceps sinensis , and a combination thereof.
66 . The method of claim 65 , wherein the oral formulation comprises from 20 wt % to 30 wt % broccoli seed extract, from 25 wt % to 35 wt % red orange extract, and from 45 wt % to 55 wt % grape seed extract.
67 . The method of claim 66 , wherein the broccoli seed extract is standardized to contain from 1 wt % to 20 wt % sulphoraphane, wherein the red orange extract is standardized to contain from 2.5 wt % to 25 wt % polyphenols, and wherein the grape seed extract is standardized to contain from 50 wt % to 99 wt % polyphenols.
68 . The method of claim 67 , wherein the administering of the oral formulation to the subject provides the subject with a daily dose of 115 mg broccoli seed extract, 125 mg red orange extract, and 210 mg grape seed extract.
69 . The method of claim 65 , wherein the oral formulation comprises from 25 wt % to 35 wt % olive leaf extract, from 5 wt % to 15 wt % olive fruit extract, from 15 wt % to 25 wt % red orange extract, from 25 wt % to 35 wt % grape seed extract, and from 5 wt % to 15 wt % coenzyme Q 10 .
70 . The method of claim 65 , wherein the oral formulation comprises from 25 wt % to 35 wt % olive leaf extract, from 5 wt % to 15 wt % olive fruit extract, from 10 wt % to 50 wt % alpha lipoic acid, from 20 wt % to 35 wt % grape seed extract, and from 5 to 15 wt % coenzyme Q 10 .
71 . The method of claim 65 , wherein the oral formulation comprises from 10 wt % to 30 wt % broccoli seed extract, from 15 wt % to 60 wt % alpha lipoic acid, and from 25 wt % to 55 wt % grape seed extract.
72 . The method of claim 65 , comprising the administering of the oral formulation to the subject occurs at night or when the subject retires to bed.
73 . The method of claim 65 , wherein the Nrf2-associated genes that are modulated include at least one gene encoding intrinsic antioxidants and at least one gene encoding cellular detoxifiers.
74 . The method of claim 65 , wherein the administering of the oral formulation to the subject attenuates inflammation by upregulating expression of intrinsic antioxidants.
75 . The method of claim 65 , wherein the administering of the oral formulation to the subject down-regulates expression of gene products that contribute to inflammatory pathways.
76 . The method of claim 65 , wherein the administering of the oral formulation to the subject up-regulates expression of anti-inflammatory proteins.
77 . The method of claim 65 , wherein the administering of the oral formulation to the subject upregulates expression of cellular detoxifiers.
78 . The method of claim 65 , wherein the administering of the oral formulation stimulates autophagy in a tissue of the subject.
79 . The method of claim 65 , wherein the administering of the oral formulation stimulates inducible autophagy and enhances responses to oxidative stress by decreasing the availability of p62.
80 . The method of claim 65 , wherein the administering of the oral formulation to the subject modulates the expression of the Nrf2-associated genes comprising a member selected from the group consisting of NFE2L2, GCLM, GCLC, GSR, GSTA1, GPX1, GPX4, SOD1, HMOX1, NQO1, SRXN1, SQSTM1, UGT1A6, NOS2, NOS3, PTGS2, and a combination thereof.
81 . The method of claim 65 , wherein the administering of the oral formulation to the subject decrease the expression of GSTA1 from 1.5 fold to 6.0 fold.
82 . The method of claim 65 , wherein the administering of the oral formulation to the subject decrease the expression of any of Gpx1, Gpx4, and SRXN1 from 1.05 fold to 4.0 fold.
83 . The method of claim 80 , wherein the administering of the oral formulation to the subject reverses a 1.1 fold to a 3.0 fold age-related downregulation of Nrf2.
84 . The method of claim 65 , wherein the administering of the oral formulation modulates the expression of at least four Nrf2-associated genes.
85 . The method of claim 65 , wherein the administering of the oral formulation modulates the expression of at least five Nrf2-associated genes.